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013.01.00Abstract Helicobacter pylori infection has been associated with digestive and rheumatic diseases.
Aim of the work: to investigate the prevalence of H. pylori in ﬁbromyalgia syndrome (FMS), to
determine the relationship between these two diseases.
Patients and methods: The present study was a cross-sectional descriptive study, 100 female
patients with primary FMS, and 100 healthy females to serve as control group were included. Serum
samples were tested for the presence of anti-H. pylori antibodies by using the enzyme-linked immu-
nosorbent assay technique.
Results: The prevalence of H. Pylori IgG antibody of the patients was signiﬁcantly higher than
the control group (68 PFMS, 32 controls p< 0.001). Also there were 50 PFMS cases and 24 con-
trols of positive IgA antibody (p< 0.001). Patients who were H. pylori IgG antibody positive when
compared to patients who were H. pylori negative, more frequently have post-exertion pain
(p= 0.0307), morning stiffness (p= 0.0177), confusion (p= 0.0139), depression (p= 0.0015),
mood disturbance (p= 0.0093), anxiety (p= 0.0388), tension headache (p= 0.0088), sleep distur-
bance (p= 0.0046), and changes in appetite (p= 0.0301). Duration of FMS in patients who were
H. pylori positive was 9.8 ± 1.8 years while in patients who were H. pylori negative it was
8 ± 2 years (p< 0.001). Patients who were H. pylori positive when compared to patients who were
H. pylori negative, had a higher visual analog scale (VAS) of fatigue (p< 0.001), VAS of global
severity (p= 0.0017), VAS of anxiety (p< 0.001), higher ﬁbromyalgia impact questionnaire
(FIQ) (p< 0.001), and more tender points count (p< 0.001).20 502366942, mobile:
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Pain, depression, sleep problems and chronic fatigue are com-
monly encountered features in patients with ﬁbromyalgia syn-
drome (FMS). Several mechanisms including central
sensitization, pain alterations in neurotransmitters and psychi-
atric comorbid conditions may be responsible for aberrant
pain processing, which may result in chronic pain and associ-
ated symptoms [1].
Environmental and genetic factors play a role in the patho-
genesis of FMS. Various triggers including trauma and stress
as well as infections, may precipitate the development of
FMS. Certain infections including hepatitis C virus, HIV
and Lyme disease have been temporally associated with the
development of FMS [2]. Endresen [3] found mycoplasma
infection in about 50% of patients with chronic fatigue syn-
drome CFS and/or FMS, in only about 10% of healthy indi-
viduals. Most patients with CFS/FMS who have
mycoplasma infection appear to recover and reach their pre-ill-
ness state after a long-term antibiotic therapy.
Infectious agents may contribute to the appearance of FMS
by activating cytokines and leading to neuroendocrine abnor-
malities [4]. As a consequence of acute or repetitive tissue inju-
ries, cytokines cause central sensitization by long-term
activation of the spinal cord glia and dorsal horn neurons [5].
Inﬂammation is an important mediator of increased sympa-
thetic nervous system activity and may lead to pain, increased
arousal, and emotional distress via mediating sympathetic ner-
vous system activity in ﬁbromyalgia patients [6].
Bacterial infections such as Helicobacter pylori (H. pylori)
play a role in some non gastrointestinal tract diseases. H. py-
lori can be a factor in the pathogenesis of coronary heart dis-
ease [7,8], RA [9], Sjogren’s syndrome [10], and Behc¸et’s
disease [11].H pylori’s effects are still incompletely understood,
H. pylori infection may cause extragastric manifestations such
as depression and anxiety, low energy, lethargy, heart palpita-
tions, headaches, and sleep problems [12,13]. H. pylori infec-
tion may cause these extragastric manifestations directly or
indirectly. The release of inﬂammatory mediators, molecular
mimicry, and systemic immune response are the suggested
mechanisms for extragastric involvement.
In Egypt, since the relation of anti-H. pylori serology and
FMS has not been investigated and there are no sufﬁcient data
in this ﬁeld, this study was conducted aiming at investigating
the anti-H. pylori-G and A immunoglobulins in patients with
FMS and comparing it to healthy population to determine the
relationshipbetween these twodiseases, and investigate the asso-
ciation betweenH. pylori and clinical characteristics of FMS.2. Patients and methods
The present study was a cross-sectional case-control descrip-
tive study which was carried out between May and September
2011 at the outpatient clinic of Rheumatology and Rehabilita-tion Department at Mansoura University Hospital, Egypt. 100
consecutive female patients with FMS were recruited. FMS pa-
tients were diagnosed according to the ACR 1990 criteria of
FMS [14].
Subjects were excluded from the study if they had an
inﬂammatory rheumatic disease, known peptic ulcer, used
antibiotics for different reasons in last 6 months, or had symp-
toms of severe gastritis.
100 healthy females among the hospital staff and some of
their relatives who were age matched to the patients were cho-
sen to serve as the control group.
Written consent was obtained from each eligible participant
in this study after approval of this study from a Local Ethics
Committee.
2.1. Clinical assessment
The eligible participants completed preliminary questionnaires
inquiring into demographic characteristics, medical history
and history of receiving any medication and then underwent a
thorough clinical examination. Pain, fatigue, anxiety and global
severity of illness were assessed using a visual analog scale (VAS)
(0–100 mm,with higher scores indicatingmore pain) [15].The 18
tender points (TPs) ofFMSwere evaluatedbypalpationwith the
pulp of the thumb at a pressure enough to blanch a thumbnail.
The following scoring system for grading the severity of TPs
was used 0 = no pain, 1 = mild (complaint of pain without gri-
mace), 2 = moderate (pain plus grimace), 3 = severe (pain plus
marked ﬂinch or withdrawal) and 4 = unbearable (patient is
‘‘untouchable’’, withdraws without palpation) [14].
The clinical severity or the current health status of the FMS
was evaluated using the Fibromyalgia Impact Questionnaire
(FIQ); a self-reported instrument consisting of 10 items (phys-
ical impairment, feel good, work missed, interference in job,
pain, fatigue, morning tiredness, stiffness, anxiety and depres-
sion). Each item was standardized on a scale ranging from 0 to
10 (with 10 indicating a greater impairment). A high total va-
lue (maximum 100) indicates severe effects on daily activities
[16]. Health related quality of life was assessed using the global
self-rating index (GSI). GSI is a self-administrated instrument
that covers 3 parts considered to be important to patients with
disorders of the locomotor system: physical condition, psycho-
logical condition and sleep disturbances. The sum of the items
results in a total 0–10 score, where 0 represents the highest
measured degree of health related quality of life [17]. Func-
tional assessment or ability is measured by using Stanford
Health Assessment Questionnaire (HAQ) which covers nine
general component categories (dressing and grooming, arising,
eating, walking, hygiene, reach, grip, outside activity, and sex-
ual activity) [18].
Sleep problem in the previous 4 weeks was assessed accord-
ing to a four-item Jenkins’ Sleep Questionnaire [19]. The Rest-
less Leg Syndrome (RLS) was diagnosed on the basis of
standard clinical criteria developed by the International RLS
Study Group [20].
Table 1 Demographic and laboratory data in FMS patients
and controls.
PFMS Controls P
Number 100 100
Age (years) 33.2 ± 4.6 33.7 ± 4.2 0.4231
Duration of symptoms (years) 8.9 ± 2.6
Number of children 2.5 ± 1.4 2.2 ± 1.6 0.1598
Employed (n, %) 38 42 0.6651
Married (n, %) 76 69 0.3421
Rural residence (n, %) 50 56 0.4788
BMI (kg/m2) 27.2 ± 3.6 26.5 ± 3.1 0.1422
Hemoglobin (gm/dl) 12.2 ± 2.3 12.7 ± 2.1 0.1100
ESR (mm/h) 23.5 ± 5.7 22.1 ± 6.3 0.1010
CRP (mg/l) 0.90 ± 0.2 0.85 ± 0.2 0.2400
H. pylori antibody
IgG+ (%) 68 32 <0.001
IgA+ (%) 50 24 <0.001
Values (±): mean ± standard deviation, BMI: body mass index,
ESR: erythrocyte sedimentation rate, FMS: ﬁbromyalgia syn-
drome, CRP: C reactive protein, H. pylori: Helicobacter pylori.
Table 2 Clinical features in FMS patients versus controls.
FMS Controls P
Fatigue 100 12 <0.001
Postexertion pain 97 7 <0.001
Depression 90 15 <0.001
Anxiety 68 14 <0.001
Morning stiﬀness (correct) 50 10 <0.001
Tension headache 60 45 0.0472
Migraine headache 45 29 0.0277
Raynaud’s phenomenon 18 7 0.0309
Dysmenorrhea 24 12 0.0419
Short memory diﬃculties 48 19 <0.001
Long memory diﬃculties 53 28 0.0084
Confusion 25 12 0.0279
Dizziness 8 1 0.0349
TMJ syndrome 9 1 0.0185
Restless leg syndrome 26 3 <0.001
Mood disturbance 22 10 0.0327
Changes in appetite 17 5 0.0115
Sleep disturbance 56 19 <0.001
Tremors 21 16 0.4667
Palpitation 55 36 0.0104
Dyspepsia 14 4 0.0238
IBS 40 21 0.0055
Breathlessness 29 19 0.1357
Genitourinary symptoms 7 1 0.0649
FIQ (mean) 51.2 ± 7.6 10.4 ± 2.3 <0.001
GSI (mean) 5.3 ± 1.2 1.7 ± 0.4 <0.001
HAQ (mean) 6.9 ± 1.5 2.2 ± 0.3 <0.001
Beck score for depression (mean) 12.4 ± 7.4 6.3 ± 2.3 <0.001
Values in percentage.
FMS: ﬁbromyalgia syndrome, TMJ: temperomandibular joint, IBS:
irritable bowel syndrome, GSI: global self-rating index, HAQ:
Health Assessment Questionnaire, FIQ: Fibromyalgia Impact
Questionnaire, TPs: tender points.
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Depression Questionnaire, a 21-item self-reported question-
naire assessing both the presence and the severity of depression
[21]. The scores of each item range between 0 and 3 (0 = least,
3 = most). The total score is the sum of all items with a max-
imum of 63. A score of P10 was considered as an indication
for clinically signiﬁcant depressive symptoms.
2.2. Laboratory assessment
At the same day of clinical evaluation, blood samples were ob-
tained from all participants at 9 a.m. after over-night fast using
aseptic venipuncture. All samples were processed in the labora-
tories of the Clinical Pathology Department of Mansoura Fac-
ulty of Medicine. Full blood count, erythrocyte sedimentation
rate, C-reactive protein, liver, kidney and thyroid function
tests were measured with routine laboratory methods in the
sera of all patients.
2.3. Serum Enzyme-Linked Immunosorbent Assay (ELISA)
testing
Serum samples were tested for the presence of anti-H. pylori
antibodies by using the pyloriset EIA-G for detection of H. py-
lori IgG in serum (Orion Diagnostica, Espoo, Finland), pylori-
set EIA-A for detection of H. pylori IgA according to
manufacturer directions.
Statistical analysis: Continuous variables are presented as
mean ± standard deviations (SD). Categorical variables are
reported as number and proportions. Data were checked for
normality and equality of distribution, prior to any analysis
being performed. Comparisons between FMS patients and
controls and also between FMS patients with H. Pylori infec-
tion and those without H. pylori infection were made using
independent t test for continuous variables. Chi-square test
was used for comparison between categorical variables. All
calculations were performed using SPSS 17.0 Software for
Windows. All analyses were 2-tailed. P values less than 0.05
were regarded as signiﬁcant.
3. Results
Baseline characteristics of the patients and controls are shown
in Table 1. One hundred women with FMS with a mean age of
33.2 ± 4.36 years and 100 healthy women age matched to the
patients participated in this study. There were no signiﬁcant
differences between both the groups in terms of age, number
of children, employment status, marital status, residence, body
mass index, hemoglobin, ESR and CRP concentration. The
prevalence of H. Pylori IgG antibody in the patients was sig-
niﬁcantly higher than the control group (68 FMS, 32 controls
p< 0.001). Also there were 50 FMS cases and 24 controls of
positive IgA antibody (p< 0.001) (Table 1).
As shown in Table 2, patients with FMS had signiﬁcantly
higher FIQ score than controls (51.2 ± 7.6 and 10.4 ± 2.3
respectively, p< 0.001). Similarly, patients with PEMS had
higher GSI score, HAQ score and more depression than con-
trols (p< 0.001). Patients with FMS were more likely than
controls to have fatigue (100% and 12% respectively), postex-
ertion pain (97% and 7% respectively), depression (90% and
15% respectively), anxiety (68% and 14% respectively), morn-ing stiffness (50% and 10% respectively), short memory difﬁ-
culties (48% and 19% respectively) sleep disturbance (56%
and 19% respectively) and restless leg syndrome (26% and
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(p< 0.001). Also, when compared to controls, FMS patients
had more frequent tension headache (p= 0.0472), migraine
headache (p= 0.0277), Raynaud’s phenomenon
(p= 0.0309), dysmenorrhea (p= 0.0419), long memory difﬁ-
culties (p= 0.0084), confusion (p= 0.0279), dizziness
(p= 0.0349), temperomandibular joint (TMJ) syndrome
(p= 0.0185), mood disturbance (p= 0.0327), changes in
appetite (p= 0.0115), palpitation (p= 0.0104), dyspepsia
(p= 0.0238), and IBS (p= 0.0055) (Table 2).
Patients who were H. pylori IgG antibody positive when
compared to patients who were H. pylori negative, more fre-
quently have post-exertion pain (100% and 90.6% respec-
tively, p= 0.0307), morning stiffness (58.8% and 21.3%
respectively, p= 0.0177), confusion (32.4% and 9.4% respec-
tively, p= 0.0139), depression (97.1% and 75% respectively,
p= 0.0015), mood disturbance (29.4% and 6.3% respectively,
p= 0.0093), anxiety (75% and 53.1% respectively,
p= 0.0388), short memory difﬁculties (55.9% and 21.3%
respectively, p= 0.0314), long memory difﬁculties (63.2%
and 21.3% respectively, p= 0.0048), tension headache
(69.1% and 40.6% respectively, p= 0.0088), Raynaud’s phe-
nomenon (23.5% and 6.3% respectively, p= 0.0494), dysmen-
orrhea (32.4% and 9.4% respectively, p= 0.0139), sleep
disturbance (66.2% and 34.4% respectively, p= 0.0046),
tremors (27.9% and 6.3% respectively, p= 0.0165), paresthe-
sia (61.8% and 28.1% respectively, p= 0.0025), RLS (33.8%
and 9.4% respectively, p= 0.0133), changes in appetite
(33.8% and 12.5% respectively, p= 0.0301), palpitation
(63.2% and 37.5% respectively, p= 0.0189), IBS (48.5%
and 21.9% respectively, p= 0.0156), breathlessness (36.8%
and 12.5% respectively, p= 0.0173) and users of H2 receptor
antagonist (75% and 37.5% respectively, p< 0.001).
Duration of FMS in patients who were H. pylori IgG posi-
tive was 9.8 ± 1.8 years while in patients who were H. pylori
negative it was 8 ± 2 years (p< 0.001). Patients who were
H. pylori positive when compared to patients who were HP
negative, had higher VAS of pain (7.9 ± 1.9 vs. 6.7 ± 1.4,
p= 0.0019), higher VAS of fatigue (8.3 ± 2.1 vs. 5.7 ± 1.8,
p< 0.001), VAS of global severity (8.9 ± 1.8 vs. 7.7 ± 1.6,
p= 0.0017), VAS of anxiety (5.5 ± 1.3 vs. 3.6 ± 1.1,
p< 0.001), higher GSI score (53.7 ± 16.8 vs. 43.8 ± 15.2,
p= 0.0056), higher HAQ score (19.4 ± 3.3 vs. 16.9 ± 2.7,
p< 0.001), higher FIQ (65.3 ± 9.1 vs. 51.4 ± 7.5,
p< 0.001), more depression (17.9 ± 7.49 vs. 14.6 ± 7.2,
p= 0.0385), more TP count (14.5 ± 1.9 vs. 12.8 ± 1.5,
p< 0.001) and higher TP score (104.4 ± 8.7 vs. 81.3 ± 6.9,
p< 0.001).4. Discussion
Helicobacter pylori is a type of bacterium that lives primarily in
the stomach and the upper part of the small intestine (duode-
num). Due to a number of factors, H. pylori infection is
increasingly recognized as highly prevalent in many popula-
tions and is of increasing health concern. H. pylori infection
has been associated with digestive diseases and rheumatic dis-
eases [22].
Wen et al. [23]found that patients of rheumatic diseases
were signiﬁcantly more likely to have H. pylori infection than
healthy control, they found that patients of RA and AS areassociated with a high prevalence of H. pylori infection rate.
H. pylori infection may play an important role in RA and AS.
Many reports concluded that H. pylori. is an initiation fac-
tor or intensiﬁer infectious agent for RA [24,25], so that its
eradication can improve the disease [25–27]. Also, patients
with Sjogren’s syndrome, or other connective tissue disorders
are more susceptible to this disease compared to normal indi-
viduals [9,10]. On the other hand, some studies have not
proved these ﬁndings [28].
Although there are several studies suggesting an association
between various infections and FMS [29,30], there are only
two studies about H. pylori infection and FMS, their results
were controversial [6,31].
In order to verify the impact of H. pylori infection on pa-
tients with FMS and to determine whether H. pylori infection
has any signiﬁcance with respect to the clinical features of
FMS, we investigated the prevalence of H. pylori in a large
number of patients with FMS.
Noninvasive techniques have high sensitivity and speciﬁcity
for the diagnosis of H. pylori infection [32]. Therefore, sero-
logic testing for antibodies to H. pylori using the ELISA has
become a widely accepted diagnostic test. These tests are also
suitable for epidemiologic studies and for the outpatient clinic
for this cross-sectional study. [32].
In this current study, we measured serum H. pylori IgA and
IgG antibodies by the ELISA technique, we found a signiﬁcant
increase in serum level of both IgA, and IgG antibodies to HP
among the FMS group than the control group. In the study of
Akkaya et al. [31], they documented a signiﬁcant HP seropos-
itivity only of H. pylori IgG antibody in the FMS group com-
pared with healthy controls. However, Malt et al. [6] did not
ﬁnd any difference for H. pylori-seropositivity between groups.
In the present investigation, the prevalence of clinical fea-
tures of FMS (pain, fatigue, morning stiffness, dysmenorrhea,
palpitations, changes in appetite, IBS) was signiﬁcantly higher
in the H. pylori-positive than -negative groups. FMS patients
with H. pylori were more likely to have a signiﬁcant impair-
ment in short & long term memory, confusion, mood distur-
bance and overall sleep disturbance. It thus seems likely that
H. pylori may contribute to the pathogenesis of FMS.
Moreover, we found a signiﬁcant increase in the duration of
symptoms, and a number of tender points and analgesic and
H2 receptor antagonist use in FMS patients with H. pylori
infection.
In this study, functional status and daily activities were im-
paired in PFM with H. pylori-positive, also they had a more
worse measured degree of health related quality of life and
more clinical severity of the current health status using FIQ
than -negative groups(Table 3).
The results of the present investigation indicate that H. py-
lori infection inﬂuenced the clinical feature severity of FMS.
However, Akkaya et al. [31] did not ﬁnd any difference
regarding the clinical features between FM patients with H.
pylori and without H. pylori.
Regarding depression, we found a signiﬁcant increase in the
incidence and severity of anxiety and depression in H. pylori-
positive than -negative FMS patients. Similarly, Malt et al.
[6] reported that HP infection might be associated with psy-
chological distress in FMS (Table 4). Malt et al. [6] suggested
that a subgroup of ﬁbromyalgia patients might suffer from H.
pylori infection with central nervous system manifestations or
alternatively, FMS patients in general may be especially vul-
Table 3 Comparison of clinical features between Hpylori IgG-positive and -negative groups.
H. pylori-positive patients (n= 68) H. pylori-negative patients (n= 32) P
N % N %
Post-exertion pain 68 100 29 90.6 0.0307
Morning stiﬀness 40 58.8 10 21.3 0.0177
Confusion 22 32.4 3 9.4 0.0139
Depression 66 97.1 24 75 0.0015
Mood disturbance 20 29.4 2 6.3 0.0093
Anxiety 51 75 17 53.1 0.0388
Dizziness 8 11.8 0 0 0.0521
Short memory diﬃculties 38 55.9 10 21.3 0.0314
Long memory diﬃculty 43 63.2 10 21.3 0.0048
Tension headache 47 69.1 13 40.6 0.0088
Migraine headache 36 52.9 9 28.1 0.0305
Raynaud’s phenomenon 16 23.5 2 6.3 0.0494
Dysmenorrhea 22 32.4 3 9.4 0.0139
Sleep disturbance 45 66.2 11 34.4 0.0046
Tremors 19 27.9 2 6.3 0.0165
Paresthesia 42 61.8 9 28.1 0.0025
RLS 23 33.8 3 9.4 0.0133
Changes in appetite 23 33.8 4 12.5 0.0301
Cardiovascular palpitation 43 63.2 12 37.5 0.0189
IBS 33 48.5 7 21.9 0.0156
Respiratory (breathlessness) 25 36.8 4 12.5 0.0173
Genitourinary symptoms 7 10.2 0 0 0. 0933
NSAIDs use 65 95.6 27 84.4 0.3105
H2 receptor antagonists use 51 75 12 37.5 <0.001
H. pylori: Helicobacter pylori, RLS: restless leg syndrome, IBS: irritable bowel syndrome, NSAIDs: non steroid anti-inﬂammatory drugs.
Table 4 Comparison of patients with FMS who are Hpylori-positive versus H. pylori-negative.
FMS
With infection (n= 68) Without infection (n= 32) P
Age (years) 33.1 ± 3.7 33.7 ± 4.1 0.4668
Duration of disease (years) 9.8 ± 1.8 8 ± 2 <0.001
VAS of pain (cm) 7.9 ± 1.9 6.7 ± 1.4 0.0019
VAS of fatigue (cm) 8.3 ± 2.1 5.7 ± 1.8 <0.001
VAS of global severity (cm) 8.9 ± 1.8 7.7 ± 1.6 0.0017
VAS of anxiety (cm) 5.5 ± 1.3 3.6 ± 1.1 <0.001
GSI score 53.7 ± 16.8 43.8 ± 15.2 0.0056
HAQ score 19.4 ± 3.3 16.9 ± 2.7 <0.001
FIQ score 65.3 ± 9.1 51.4 ± 7.5 <0.001
Beck score for depression 17.9 ± 7.4 14.6 ± 7.2 0.0385
TPs count 14.5 ± 1.9 12.8 ± 1.5 <0.001
TPs score 104.4 ± 8.7 81.3 ± 6.9 <0.001
ESR (mm/h) 17.8 ± 6.5 16.2 ± 5.7 0.2359
CRP (mg/l) 0.35 ± 0.3 0.33 ± 0.2 0.7327
Values (±): mean ± standard deviation, H. pylori: Helicobacter pylori, VAS: visual analog scale, joint, GSI: global self-rating index, FMS:
ﬁbromyalgia syndrome, HAQ: Health Assessment Questionnaire, FIQ = Fibromyalgia Impact Questionnaire, TPs: tender points, ESR:
erythrocyte sedimentation rate, CRP: C reactive protein.
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Akkaya et al. [31] found that depression subscale of FIQ, mean
anxiety VAS of FIQ, history of depression, and previous
depression treatment were not different between ﬁbromyalgia
patients with HP and without H. pylori. This difference may
be due to the evaluation method of the psychological state of
patients in the study of Akkaya et al. [31]. They used depres-sion and anxiety subscales of FIQ and patients’ own expres-
sion for depression history, while in our study, we used the
Beck depression questionnaire; a more speciﬁc evaluation
method.
Also, we found that H. pylori-positive FMS patients have
more migrinous attack. Our results may be explained by the re-
sults of a study done by Gasbarrini et al. [33], they found the
172 S.M. Olama, M. El-ArmanH. pylori infection coincides with the severity of the migraine
headache and also with the progressive stage of the migraine
symptoms, they considered this infection as one etiology of
the migraine headache signiﬁcantly if not totally, more impor-
tantly than other immunological properties. Also, Hossein-
zadeh et al. [34] found H. pylori infection is strongly related
to the outbreak and severity of migraine headaches, and H. py-
lori treatment reduces migraine headaches signiﬁcantly. This
may be due to the fact that this bacterium can cause the secre-
tion of serotonin from platelets, consequently it can play a role
in creating migraine headaches by increased secretion of
serotonin.
In this study, we did not ﬁnd any difference for ESR and
CRP levels between FMS and the control group and also be-
tween the FMS group with H. pylori and the FMS group with-
out H. pylori. Similar results were obtained from the study of
Akkaya et al. [31].
To the best of our knowledge, our study is the ﬁrst to assess
the relationship between H. pylori and FMS in Egypt. This
comprehensive study is the ﬁrst report from Egypt.
By means of causation and therapy, H. pylori infection may
permit a further subclassiﬁcation of FMS.
In conclusion, according to our results, the signiﬁcant in-
crease existing in IgG and IgA antibody titer against H. pylori
in FMS compared to control groups shows the importance of
studying HP infection in FMS patients, and also gives rise to a
hope that a deﬁnite treatment and eradication of this bacte-
rium can cure or reduce the severity and course of FMS caused
by this bacterium signiﬁcantly if not totally.
More controlled trials are suggested in order to clarify the
relationship between HP infection and FMS.Conﬂict of interest
The authors disclose no conﬂict of interest.References
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